Press-release for stocks published on this month

Prices are updated after-hours

positive published : This month

save search

Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ACRV | $9.46 -3.67% -3.81% 300K

| Email alert Add to watchlist
acr-368 positive pipeline for program therapeutics today

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date April 15, 2024
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
NDAQ | $61.51 0.69% 0.68% 2.8M

Finance

| Email alert Add to watchlist
nasdaq

BioStem Technologies Inc. Completes Two-Year Audit, Prepares for Uplisting to Senior ExchangeStrategic Audit Completion Set to Enhance BioStem Technologies' Market Position and Shareholder Value
Published: 2024-04-24 (Crawled : 15:00) - biospace.com/
BSEM | $9.24 -38.71% 32K

n/a

| 1.3% | O: 0.0% H: 1.73% C: 1.3%
for set market

Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CAPR | $5.04 4.56% 4.37% 910K

Health Technology

| 4.56% | O: 9.13% H: 7.41% C: -4.18%
cap-1002 fda positive program therapeutics duchenne type-b meeting

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
GANX | $3.16 -6.78% -7.28% 150K

Professional, Scientific, and T...

| -5.9% | O: 4.42% H: 3.11% C: -9.89%
gt-0228 disease positive for parkinson’s trial therapeutics therapy results

Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Published: 2024-04-24 (Crawled : 13:00) - globenewswire.com
CYTO | $1.495 -5.38% -5.69% 3M

Manufacturing

| -8.86% | O: 1.27% H: 0.0% C: -10.0%
positive publication bentrio trial therapeutics results

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
IMMP | $2.59 3.19% 3.09% 1.4M

Health Technology

| 6.58% | O: 14.4% H: 8.99% C: -6.83%
tacti-003 positive topline results

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
NVNO | $5.27 -4.18% -4.36% 100K

Manufacturing

| 2.35% | O: 9.8% H: 0.0% C: -6.79%
symposium positive topline trial today

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
Published: 2024-04-24 (Crawled : 12:00) - biospace.com/
INVA | $15.15 -0.13% -0.13% 420K

Health Technology

| 0.9% | O: 1.03% H: 0.72% C: -0.13%
positive treatment global for

Argentina Lithium Announces Positive Lithium Values in the 12th Exploration Well at the Rincon West Project
Published: 2024-04-24 (Crawled : 11:00) - prnewswire.com
STLA | $24.86 -0.4% 0.2% 5.3M

Manufacturing

| -0.04% | O: 0.32% H: 0.2% C: -0.36%
west lithium positive

Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
Published: 2024-04-24 (Crawled : 11:00) - hancockjaffe.com
NVNO | $5.27 -4.18% -4.36% 100K

Manufacturing

| 2.35% | O: 9.8% H: 0.0% C: -6.79%
venovalve symposium positive topline trial today

Calliditas Announces Positive NefIgArd Open Label Extension Results
Published: 2024-04-24 (Crawled : 08:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K

Health Technology

| 1.65% | O: 3.46% H: 0.0% C: -1.75%
label positive nefigard extension results

Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria
Published: 2024-04-24 (Crawled : 05:00) - globenewswire.com
NVS | News | $98.35 1.1% 0.0% 2.2M

Health Technology

| -0.52% | O: -0.36% H: 0.05% C: -0.15%
malaria positive treatment for novartis

Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K

Health Technology

| -0.97% | O: -0.11% H: 0.0% C: 0.0%
NBIX | News 4 | $138.91 -0.84% -0.85% 880K

Health Technology

| 3.97% | O: 5.49% H: 2.84% C: -0.65%
nbi-1065 positive for

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
TARS | $32.77 -2.79% -2.87% 320K

Health Technology

| -0.4% | O: -2.28% H: 6.13% C: 4.88%
million financial

Snail Inc Elevates Its Market Position with the Launch of Bellwright in Early Access
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
SNAL | $1.068 1.96% 23K

| 1.89% | O: 0.0% H: 3.77% C: 0.94%
market

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.26 1.88% 1.84% 450K

Health Technology

| 21.72% | O: 12.36% H: 8.33% C: 6.67%
atile-002 versamune biotech hpv cancer key trial

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
SILO | $1.9 6.74% 6.32% 380K

Finance and Insurance